These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 39187068)

  • 21. Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study.
    Tini G; Milani P; Zampieri M; Caponetti AG; Fabris F; Foli A; Argirò A; Mazzoni C; Gagliardi C; Longhi S; Saturi G; Vergaro G; Aimo A; Russo D; Varrà GG; Serenelli M; Fabbri G; De Michieli L; Palmiero G; Ciliberti G; Carigi S; Sessarego E; Mandoli GE; Ricci Lucchi G; Rella V; Monti E; Gardini E; Bartolotti M; Crotti L; Merli E; Mussinelli R; Vianello PF; Cameli M; Marzo F; Guerra F; Limongelli G; Cipriani A; Perlini S; Obici L; Perfetto F; Autore C; Porto I; Rapezzi C; Sinagra G; Merlo M; Musumeci B; Emdin M; Biagini E; Cappelli F; Palladini G; Canepa M
    Eur J Heart Fail; 2023 Jun; 25(6):845-853. PubMed ID: 36907828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?
    Razvi Y; Ioannou A; Patel RK; Chacko L; Karia N; Riefolo M; Porcari A; Rauf MU; Starr N; Ganesananthan S; Blakeney I; Kaza N; Filisetti S; Bolhuis RE; Rowczenio D; Gilbertson J; Hutt D; Mahmood S; Lachmann HJ; Wechalekar AD; Kotecha T; Knight DS; Coghlan JG; Petrie A; Whelan CJ; Venneri L; Martinez-Naharro A; Hawkins P; Fontana M; Gillmore JD
    Eur J Heart Fail; 2024 Feb; 26(2):383-393. PubMed ID: 37953725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders.
    López-Sainz Á; de Haro-Del Moral FJ; Dominguez F; Restrepo-Cordoba A; Amor-Salamanca A; Hernandez-Hernandez A; Ruiz-Guerrero L; Krsnik I; Cobo-Marcos M; Castro V; Toquero-Ramos J; Lara-Pezzi E; Fernandez-Lozano I; Alonso-Pulpon L; González-López E; Garcia-Pavia P
    Amyloid; 2019 Sep; 26(3):156-163. PubMed ID: 31210553
    [No Abstract]   [Full Text] [Related]  

  • 24. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).
    Phull P; Sanchorawala V; Connors LH; Doros G; Ruberg FL; Berk JL; Sarosiek S
    Amyloid; 2018 Mar; 25(1):62-67. PubMed ID: 29424556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic.
    Lindmark K; Pilebro B; Sundström T; Lindqvist P
    ESC Heart Fail; 2021 Feb; 8(1):745-749. PubMed ID: 33205581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prevalence of transthyretin cardiac amyloidosis in patients hospitalized for heart failure with preserved ejection fraction and septal thickness].
    Decotto S; Fernández Villar G; Llamedo MC; Villanueva E; Pérez De Arenaza D; Lucas L; Del Castillo S; Rossi E; Belziti C; Pizarro R
    Medicina (B Aires); 2024; 84(5):823-830. PubMed ID: 39399922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; Davies DR; Scott CG; Fayyaz AU; Askew JW; McKie PM; Noseworthy PA; Johnson GB; Dunlay SM; Borlaug BA; Chareonthaitawee P; Roger VL; Dispenzieri A; Grogan M; Redfield MM
    JAMA Cardiol; 2021 Nov; 6(11):1267-1274. PubMed ID: 34431962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
    Lyng CS; Gude E; Hodt A; Knudsen EC
    Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
    Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
    JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis.
    Driggin E; Maurer MS
    Clin Cardiol; 2020 Feb; 43(2):171-178. PubMed ID: 31825134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gait abnormalities in older adults with transthyretin cardiac amyloidosis.
    Petros FE; Santos AM; Adeniyi A; Teruya S; De Los Santos J; Maurer MS; Agrawal SK
    Amyloid; 2024 Jun; 31(2):116-123. PubMed ID: 38433466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atrial function and geometry differences in transthyretin versus immunoglobulin light chain amyloidosis: a cardiac magnetic resonance study.
    Palmer C; Truong VT; Slivnick JA; Wolking S; Coleman P; Mazur W; Zareba KM
    Sci Rep; 2022 Jan; 12(1):140. PubMed ID: 34996915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan.
    Yamada T; Takashio S; Arima Y; Nishi M; Morioka M; Hirakawa K; Hanatani S; Fujisue K; Yamanaga K; Kanazawa H; Sueta D; Araki S; Usuku H; Nakamura T; Suzuki S; Yamamoto E; Ueda M; Kaikita K; Tsujita K
    ESC Heart Fail; 2020 Oct; 7(5):2829-2837. PubMed ID: 32672425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness.
    Holcman K; Kostkiewicz M; Szot W; Ćmiel B; Mróz K; Stępień A; Graczyk K; Dziewięcka E; Karabinowska-Małocha A; Sachajko Z; Podolec P; Rubiś P
    Int J Cardiovasc Imaging; 2024 Aug; 40(8):1693-1703. PubMed ID: 38856962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence, incidence and clinical outcomes of epicardial coronary artery disease among transthyretin amyloidosis cardiomyopathy patients.
    Hassan R; Miller RJH; Howlett JG; White JA; Fine NM
    BMC Cardiovasc Disord; 2023 Mar; 23(1):124. PubMed ID: 36890444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.
    Narotsky DL; Castano A; Weinsaft JW; Bokhari S; Maurer MS
    Can J Cardiol; 2016 Sep; 32(9):1166.e1-1166.e10. PubMed ID: 27568874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver stiffness as a prognostic parameter and tool for risk stratification in advanced cardiac transthyretin amyloidosis.
    Ihne-Schubert SM; Morbach C; Goetze O; Cejka V; Steinhardt MJ; Frantz S; Einsele H; Sommer C; Störk S; Schubert T; Geier A
    Clin Res Cardiol; 2024 Aug; ():. PubMed ID: 39164508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in the characteristics and contemporary cardiac outcomes of patients with light-chain versus transthyretin cardiac amyloidosis.
    Itzhaki Ben Zadok O; Vaturi M; Vaxman I; Iakobishvili Z; Rhurman-Shahar N; Kornowski R; Hamdan A
    PLoS One; 2021; 16(8):e0255487. PubMed ID: 34370783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transthyretin amyloidosis: Putting myopathy on the map.
    Pinto MV; Milone M; Mauermann ML; Dyck PJB; Alhammad R; McPhail ED; Grogan M; Liewluck T
    Muscle Nerve; 2020 Jan; 61(1):95-100. PubMed ID: 31587306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regional Variation in Technetium Pyrophosphate Uptake in Transthyretin Cardiac Amyloidosis and Impact on Mortality.
    Sperry BW; Vranian MN; Tower-Rader A; Hachamovitch R; Hanna M; Brunken R; Phelan D; Cerqueira MD; Jaber WA
    JACC Cardiovasc Imaging; 2018 Feb; 11(2 Pt 1):234-242. PubMed ID: 28917675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.